
Dexmedetomidine-based intravenous sedation of a Glucose-6-phosphate dehydrogenase deficiency pediatric patient: A case report Nanae Takahashi¹⁾ Takashi Ogawa²⁾ Yuichi Sato¹⁾ Masato Takahashi³⁾ Tomoka Matsumura¹⁾ Haruhisa Fukayama⁴⁾ and Akibumi Omi¹⁾

 ¹⁾Department of Anesthesiology, ²⁾Department of Oral and Maxillofacial Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
 ³⁾Department of Oral and Maxillofacial Surgery, Kamagaya General Hospital, Chiba, Japan
 ⁴⁾Department of Anesthesiology and Clinical Physiology, Tokyo Medical and Dental University, Tokyo, Japan

Introduction

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a very common X-linked genetic disorder caused by a structural abnormality in the G6PD enzyme. The G6PD enzyme catalyzes the first step in the pentose phosphate pathway, leading to antioxidants that protect red-blood-cells against oxidative damage. G6PD deficiency can cause hemolytic anemia, usually after exposure to certain medications, foods, and infections. Therefore, clinical management of G6PD deficiency is to prevent hemolysis caused by oxidant stress from certain drugs, and severe infections. To the best of our knowledge, this is the first reported case of dexmedetomidine-based intravenous sedation used in a G6PD deficiency patient.

Fig.1. Pentose-phosphate pathway



Patient and Methods Patient

The patient was a 5-year-old boy (height 115 cm, body weight 22 kg) with G6PD deficiency. He had no previous medical history of hemolytic anemia. He did not have any problems when he took painkillers or cold medicines. The patient's grandfather, who was of Taiwanese origin, also had G6PD deficiency; however, the grandfather also had never developed a hemolytic reaction. The patient had mild amblyopia and a mild mental retardation. We performed frenectomy under intravenous sedation.

Methods

We used dexmedetomidine-based intravenous sedation. Dexmedetomidine has been reported to have antioxidant activity, to cause less respiratory depression than other sedatives, and to be effective for pediatric sedation. And, we used other sedative drugs before using dexmedetomidine, to avoid a change in circulation at the time of dexmedetomidine loading. His vital signs were stable and maintained a Ramsay Score of 4.



Fig.2. Patient's G6PD enzyme data

Normal range (mean ± SD)	Control	Our patient
(7.61–9.81) (IU/gHb)	10.2	0.7

Fig.3.Patient's family G6PD deficiency Normal Patient's grandfather

Anesthesia Chart

Allestilesia Ullart		
Time 10:	0:00 🔽 🔽	1:00
O_2 (L/min)) 3	
2% Xylocaine (1/80,000 E)(ml)		
Fentanyl (µg)) 25	
Midazolam (mg)) 1 1	
Dexmedetomidine (µg/kg/h)) 0.7	
$\operatorname{SpO2}$	2 99 100 100 100 100 100	
Respiration (rate / min)) 24 22 22 22 22 22	
Transfusion (mL)		
Ê 120	20	
HR (Hart rate) • 120 Systelic pressure		
Systolic pressure \underbrace{H}_{b0} 80	30	





	Fig.4. WHO classificat	ion of G6PD deficiency		
:00	Class I Severely deficie	nt chronic hemolytic anemia		
	Class II 1%-10% residual activity Our patient			
	Class II 10%-60% residual activity			
	Class IV 60%-150% normal activity			
	Class V >150 % increased activity			
Variants of G6PD deficiency are grouped into 5 classes based on their enzyme activity and clinical manifestations.				
	Bull World Health Organ 198			
	G6PD deficiency	Dexmedetomidine		
	symptom Triggers			
	 infection 			
	oxidant drugs	CH ₃		
	(antipyretic or	HN		



Results

During dexmedetomidine-based intravenous sedation, good respiratory and circulatory states were maintained. No problems occurred in the perioperative period; signs of hemolysis such as fatigue, headache, and dark urine were not observed.

Conclusions

Our case suggests that the selection and use of sedatives with anti-oxidant and inflammatory effects to counter the rise in perioperative oxidative stress will increase safety. Dexmedetomidine was safe and effective for this pediatric patient with G6PD deficiency. We suggest that Dexmedetomidine will be one of the safe drugs that can be used for pediatric patient with G6PD deficiency.

References

M D Cappellini, G Fiorelli .Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008;371:64-74

Philip J Mason et al. G6PD deficiency: the genotype-phenotype association. Blood Reviews 2007;21:267-283

Elyassi AR Rowshan HH. Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: areview of literature. Anesth Prog;2009;56:86-91